Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of sotagliflozin in type 2 diabetes mellitus with moderate renal impairment
MOH_2017-09-24_000750Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2017-09-24_000750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-24_000750.